0
0
Breakthrough Study Identifies Potential New Alzheimer’s Therapy
Researchers from the University of California, San Francisco (UCSF), and the Gladstone Institutes have identified a promising new approach for treating Alzheimer’s disease by repurposing two FDA-approved cancer drugs. Their findings provide hope that these medications, when used together, could help reverse or slow cognitive decline in the most common form of dementia.
How the Discovery Was Made
The team analyzed gene expression patterns from single cells of human brains affected by Alzheimer’s disease, using data from three publicly available studies. They compared these patterns to the effects of 1,300 already-approved drugs, searching for compounds that could reverse the harmful gene expression changes seen in both neurons and glial cells.
Through this approach, they identified 86 drugs with positive effects in at least one brain cell type, and 25 that worked in multiple types. Narrowing the list further, they found that only 10 of these were already FDA-approved. By reviewing health data from 1.4 million individuals over age 65, the scientists observed that some patients who took several of these drugs as cancer treatments had a reduced risk of developing Alzheimer’s disease.
The Two Cancer Drugs: Letrozole and Irinotecan
With this evidence in hand, the researchers selected two cancer drugs for laboratory testing:
-
Letrozole, typically prescribed for breast cancer, showed promise for reversing disease-related changes in neurons.
-
Irinotecan, a treatment for colon and lung cancer, appeared to help glial cells.
They tested the drugs—individually and in combination—on mice genetically engineered to develop an aggressive form of Alzheimer’s disease. In the animal models, treatment with both drugs not only corrected disease-linked gene expression but also reduced toxic protein clumps, prevented brain degeneration, and restored memory.
Next Steps: Toward Clinical Trials
The scientists emphasize that this dual-drug approach, rooted in computational and experimental analysis, is poised for clinical trial evaluation in Alzheimer’s patients. Their work suggests that combining therapies targeting different brain cell types may be key to addressing the complexity of Alzheimer’s disease.
“If completely independent data sources, such as single-cell expression data and clinical records, guide us to the same pathways and the same drugs, and then resolve Alzheimer’s in a genetic model, then maybe we’re onto something,” said Dr. Marina Sirota, co-senior author of the study.
A Glimpse of Hope for Millions
Alzheimer’s disease afflicts over 7 million Americans and is known for relentlessly eroding memory, cognition, and the ability to learn. Existing treatments have fallen short of meaningfully slowing the disease’s progress, underscoring the importance of new, data-driven approaches.
Disclaimer
The findings discussed are based on preclinical research and analysis of health records. While the results in animal models are encouraging, the combination of letrozole and irinotecan has not yet been tested for safety or effectiveness in people with Alzheimer’s disease. Further studies, including clinical trials, are required before these drugs can be recommended for treating dementia. Patients should not attempt to use these medications for Alzheimer’s without medical supervision.
